RFA-ES-22-007: Utilizing Telomere Status to Reveal Molecular Mechanisms Underlying Susceptibility and Resiliency in Response to Environmental Exposures (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on February 14, 2023.
From the official notice on Grants.gov, last changed October 21, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIEHS
- Median yearly award$487,001
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-ES-22-007 were run by National Institute of Environmental Health Sciences (NIEHS, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-ES-22-007 in the NIH Guide.
Key dates
| Posted | October 21, 2022 |
|---|---|
| Deadline | February 14, 2023 |
| Archived by Grants.gov | March 22, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (81% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this funding opportunity announcement (FOA) is to solicit applications that further examine and characterize molecular underpinnings surrounding telomere status and accompanying biological pathways in response to environmental insults. Specifically, the intent is to further stimulate the field on how general telomere maintenance modulates downstream biological pathway(s) leading to cellular and organismal dysfunction. It is anticipated that proposed studies examining exposure affects at telomeric regions can actually potentiate early onset of age-related diseases. This FOA ultimately seeks to identify key mechanistic insights into telomere dynamics and how this could better dissect the interplay between environmental exposures at this vulnerable site contribute to disease (e.g., cancer, CVD, and other age-related outcomes, such as neurodegeneration).
Funded under RFA-ES-22-007 so far
NIH funded 4 projects under RFA-ES-22-007 in fiscal 2024 to 2026, at 4 institutions. The median yearly award was $487,001.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Telomere dysfunction driven molecular outputs in the cardiac unit | University of Pittsburgh at Pittsburgh | 2026 | $566,000 |
| Early-life environmental exposure mixtures and biological age acceleration in children and adolescents: susceptibility, potential interactions and underlying mechanisms | Icahn School of Medicine at Mount Sinai | 2026 | $518,142 |
| Telomere uncapping epigenetically reprograms a stress response and longevity pathway | Univ of North Carolina Chapel Hill | 2026 | $487,001 |
| Impact of Phthalate Exposure on Telomere Biology in Utero | New York University School of Medicine | 2026 | $359,000 |
Who has won Environmental Health grants before
From fiscal 2021 to 2025, Environmental Health (93.113) awarded $2.1 billion across 1,980 grant awards, an average of $1.1 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | 49 | $87.7 million |
| The Trustees of Columbia University in the City of New York | New York | 69 | $78.7 million |
| University of North Carolina at Chapel Hill | North Carolina | 59 | $71.5 million |
| Emory University | Georgia | 57 | $67.2 million |
| University of Southern California | California | 40 | $58.9 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-ES-22-007 still open?
No. It closed on February 14, 2023.
Who can apply for Utilizing Telomere Status to Reveal Molecular Mechanisms Underlying Susceptibility and Resiliency in Response to Environmental Exposures (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Utilizing Telomere Status to Reveal Molecular Mechanisms Underlying Susceptibility and Resiliency in Response to Environmental Exposures (R01 Clinical Trial Not Allowed)?
Closed February 14, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-ES-22-007?
NIH RePORTER lists 4 projects funded under RFA-ES-22-007 in fiscal 2024 to 2026, at 4 institutions. The most were at University of Pittsburgh at Pittsburgh, Icahn School of Medicine at Mount Sinai, Univ of North Carolina Chapel Hill.
Who has won Environmental Health grants before?
The largest recipients over five fiscal years were Icahn School of Medicine at Mount Sinai, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill. The program made 1,980 awards worth $2.1 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)